Yeah, but do you trust the FDA/BP? Who knows what other roadblocks they'll throw up. I have zero doubt that if leronlimab was a product of a BP, it would have already been FDA approved years ago.

NP keeps crediting the FDA with giving approval for clinical trials in record time, but remember the context; FDA is doing this in a time where they are expediting EVERYONE's request due to the pandemic. NP is giving the FDA UNDUE credit.

I have significant concerns that the FDA will come up with other excuses to slow down leronlimab's use. And each new requirements will be "just" a little more like a carrot on a stick. I hope I am wrong, but so far, this has been my experience with CYDY in the ~2 months I've owned shares. I wonder how many long time investors feel this way, albeit, many benefited enormously with the bump in SP from pennies to $3.